Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies Azafaros, a clinical-stage biotechnology company with a specialized focus on rare lysosomal storage disorders (LSDs), announced the successful completion of a €132 million ($142 million USD equivalent) Series…
A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal patch delivering 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol…
AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) for patients with high-risk non-muscle-invasive…
GSK Reports Positive Phase III Results for Linerixibat in Treating Itch Associated with PBC GSK plc (LSE/NYSE: GSK) today announced positive results from its GLISTEN phase III trial evaluating linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, in adults…
90% of Adults with Chronic Hepatitis Delta Who Cleared Virus on Bulevirtide Stayed Clear Nearly 2 Years After Stopping Treatment Gilead Sciences, Inc. (Nasdaq: GILD) today announced final results from the Phase 3 MYR301 study showing that nearly 90% of…
Enhertu Plus THP Shows Improved Safety and Efficacy Over Standard of Care in Early HER2-Positive Breast CancerAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by a regimen of paclitaxel, trastuzumab, and pertuzumab (THP), has shown a significantly improved safety profile…
TREMFYA® Shows Sustained Long-Term Remission in Ulcerative Colitis Patients, According to Phase 3 QUASAR LTE Study More than 70% of patients in clinical remission and over 40% in endoscopic remission at Week 92 Johnson & Johnson (NYSE: JNJ) today announced…
AstraZeneca’s Breztri Achieves Primary Endpoints in KALOS and LOGOS Phase III Trials, Marking a Significant Advance in the Treatment of Uncontrolled Asthma AstraZeneca announced encouraging high-level results from its pivotal Phase III KALOS and LOGOS clinical trials evaluating Breztri Aerosphere…
Vaccine Study Shows Fewer Side Effects with PharmaJet Needle-Free Delivery PharmaJet®, a company committed to advancing the performance, safety, and effectiveness of injectable vaccines and therapies through innovative needle-free injection technology, has announced the publication of a significant new study…
AI-Driven HSS Study Identifies Risk Factors for Severe Pain After Knee Replacement At the 50th Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA), a groundbreaking study utilizing artificial intelligence (AI) to classify patient pain archetypes…
New SURPASS-3 Data Links Tirzepatide to Muscle Composition Changes in Type 2 Diabetes In an increasingly dynamic and rapidly evolving field of metabolic disease management, the nuanced effects of weight loss therapies on body composition are gaining heightened scientific and…
Predicta Biosciences Unveils First Molecular Diagnostic for Enhancing Multiple Myeloma Prognosis Predicta Biosciences, a precision oncology company, has officially launched its first Laboratory Developed Test (LDT), GenoPredicta, a cutting-edge diagnostic tool designed for use in both blood and bone marrow…
